Drug Trial Radar · NCT07178730
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
765
Planned (sponsor's estimate)
Start
Aug 30, 2026
Primary completion
Mar 31, 2033
Study completion Mar 31, 2033
Sponsor
- Lead sponsor
- Women's Cancer Study Group GmbHAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Gilead Sciences
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TNBC is a heterogeneous disease with distinct pathological, genetic, and clinical features among subtypes. Treatment results for high-risk primary TNBC remain poor compared to other breast cancer subtypes. Preoperative chemotherapy is the standard of care for patients with stage II or III primary TNBC. Multiple lines of clinical evidence demonstrate that TNBC patients who achieve a pCR to NACT, (ypT0/is ypN0), have an excellent long-term prognosis. A meta-analysis of individual patient data confirmed a strong association of pCR after NACT with improved long-term event-free survival (EFS, hazard ratio \[HR\] 0.24) and overall survival (OS, HR 0.16) benefit. Taxane- and anthracycline-based neoadjuvant regimens generally result in pCR rates between 25-50% \[REFs\], whereas the addition of platinum increases pCR rates to approximately 50-55%. The KEYNOTE-522 trial has demonstrated that the addition of the immune-checkpoint inhibitor PEM to anthracycline- (AC), taxane- and platinum-based NACT resulted in a significant increase in pCR rates to nearly 65%, associated with a significant reduction of recurrences (EFS, HR 0.65 at 5 years) and improvement of OS (HR 0.66). Based on these results, the KEYNOTE-522 regimen has been approved by the FDA and EMA and has become the standard of care for patients with stage II or III TNBC. Despite this significant progress, two major questions remain unresolved which will be investigated in the ADAPT-TN-IV trial: 1. Do all patients require the full 6 months of NACT as per KEYNOTE-522 or is there a subgroup of patients who are sufficiently treated with 12 weeks of NACT plus PEM? 2. Can incorporation of ADCs into the KEYNOTE-522 regimen improve response and outcomes in patients without an optimal early response? The outcome of patients with residual disease after 24 weeks of NACT and PEM remains suboptimal and there is an urgent need for more effective strategies. ADCs such as SG have demonstrated superior efficacy compared to standard chemotherapy in metastatic TNBC, resulting in substantially higher response rates and improved progression-free (PFS) and OS. Combination studies of ADCs and immunotherapy in metastatic TNBC have demonstrated significant activity, suggesting possible synergistic activity It is therefore a logical next step to investigate, whether the incorporation of SG in the NACT regimen can improve pCR rates and EFS results in patients who have residual clinical disease after 12 weeks of NACT with CARBO/PAC + PEM.
Conditions
- Breast Cancer
- Triple-negative Breast Cancer
Interventions
Sacituzumab govitecanDrug
SG is administered at 10 mg/kg as an intravenous (i.v.) infusion on Days 1 and 8 of a 21-day cycle. The dose of SG will be calculated based on actual weight at randomization (using weight obtained either at enrolment or on Cycle 1 Day 1) and remains constant throughout the study, unless there is a \> 10% change in body weight from baseline. Modifications to the study drug doses administered should be made for a \> 10% change in body weight from baseline and according to local and regional prescribing standards. Dose modifications for changes in body weight \< 10% may be made according to local institutional guidelines. SG is administered via i.v. infusion as described below with additional information available in the current version of the SmPC.
Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]Drug
Pembrolizumab 200 mg will be administered as a 30-minute i.v. infusion every 3 weeks.
SoC ChemotherapyDrug
Standard of care chemotherapy as per common treatment guidelines and recommendations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort I: 3-year event-free survival (EFS)Time frame: EFS 3 years
- Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to event-free survival (EFS)Time frame: EFS 3 years
- Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to pathological complete response (pCR) ratesTime frame: EFS 3 years
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
University Medical Center Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
Hamburg, Germany
SLK-Kliniken Heilbronn GmbH, Klinik für Gynäkologie und Geburtshilfe
Heilbronn, Baden-Wurttemberg, Germany
GRN Gesundheitszentren Rhein-Neckar gGmbH, Brustzentrum Weinheim
Weinheim, Baden-Wurttemberg, Germany
Universitaetsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtsmedizin
Augsburg, Bavaria, Germany
Klinikum der Universitaet Muenchen AöR, Frauenheilkunde und Geburtshilfe
München, Bavaria, Germany
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Brustzentrum
München, Bavaria, Germany
Caritas-Krankenhaus St. Josef, Frauenheilkunde und Geburtshilfe
Regensburg, Bavaria, Germany
Haematologisch Onkologische Schwerpunktpraxis
Würzburg, Bavaria, Germany
Medical University Of Lausitz Carl Thiem, Frauenklinik
Cottbus, Brandenburg, Germany
Gesundheitszentrum Wetterau gGmbH, Gynäkologische Ambulanz
Bad Nauheim, Hesse, Germany
Klinikum Kassel GmbH, Klinik für Frauenheilkunde und Geburtshilfe
Kassel, Hesse, Germany
Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz
Hildesheim, Lower Saxony, Germany
Universitaetsklinikum Aachen AöR, Gynäkologie und Geburtsmedizin
Aachen, North Rhine-Westphalia, Germany
Universitaetsklinikum Bonn AöR, Senologie
Bonn, North Rhine-Westphalia, Germany
University Hospital Cologne AöR, Brustkrebszentrum
Cologne, North Rhine-Westphalia, Germany
Klinikum Dortmund gGmbH, Frauenklinik Dortmund
Dortmund, North Rhine-Westphalia, Germany
St.-Antonius-Hospital gGmbH, Klinik für Hämatologie und Onkologie
Eschweiler, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen AöR Klinik für Frauenheilkunde und Geburtshilfe
Essen, North Rhine-Westphalia, Germany
Onkodok GmbH Onkologische Gemeinschaftspraxis
Gütersloh, North Rhine-Westphalia, Germany
St. Barbara-Klinik Hamm GmbH, Brustzentrum
Hamm, North Rhine-Westphalia, Germany
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
Mönchengladbach, North Rhine-Westphalia, Germany
St. Franziskus-Hospital GmbH, MVZ MediaVita
Münster, North Rhine-Westphalia, Germany
MKS St. Paulus GmbH, Märkisches Brustzentrum
Schwerte, North Rhine-Westphalia, Germany
Praxisnetz Hämatologie / internistische Onkologie
Troisdorf, North Rhine-Westphalia, Germany
Marien-Hospital Witten, Brustzentrum
Witten, North Rhine-Westphalia, Germany
Klinikum Obergoeltzsch Rodewisch Frauenklinik / Brustzentrum
Rodewisch, Saxony, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.